These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28894043)

  • 1. Immune disorders in sepsis and their treatment as a significant problem of modern intensive care.
    Łysenko L; Leśnik P; Nelke K; Gerber H
    Postepy Hig Med Dosw (Online); 2017 Aug; 71(1):703-712. PubMed ID: 28894043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in sepsis induced immunosuppression and immunomodulation therapy].
    He X; Bo L; Jiang C
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Dec; 30(12):1202-1205. PubMed ID: 30592959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?
    Boomer JS; Green JM; Hotchkiss RS
    Virulence; 2014 Jan; 5(1):45-56. PubMed ID: 24067565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
    Patil NK; Bohannon JK; Sherwood ER
    Pharmacol Res; 2016 Sep; 111():688-702. PubMed ID: 27468649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
    Meisel C; Schefold JC; Pschowski R; Baumann T; Hetzger K; Gregor J; Weber-Carstens S; Hasper D; Keh D; Zuckermann H; Reinke P; Volk HD
    Am J Respir Crit Care Med; 2009 Oct; 180(7):640-8. PubMed ID: 19590022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.
    Shindo Y; Unsinger J; Burnham CA; Green JM; Hotchkiss RS
    Shock; 2015 Apr; 43(4):334-43. PubMed ID: 25565644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the understanding and treatment of sepsis-induced immunosuppression.
    Venet F; Monneret G
    Nat Rev Nephrol; 2018 Feb; 14(2):121-137. PubMed ID: 29225343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracorporeal therapies in sepsis.
    Panagiotou A; Gaiao S; Cruz DN
    J Intensive Care Med; 2013; 28(5):281-95. PubMed ID: 22027760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options.
    Liu D; Huang SY; Sun JH; Zhang HC; Cai QL; Gao C; Li L; Cao J; Xu F; Zhou Y; Guan CX; Jin SW; Deng J; Fang XM; Jiang JX; Zeng L
    Mil Med Res; 2022 Oct; 9(1):56. PubMed ID: 36209190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy.
    Monneret G; Venet F
    Cytometry B Clin Cytom; 2016 Jul; 90(4):376-86. PubMed ID: 26130241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunomodulation for sepsis: a change of tack?].
    Leentjens J; Kox M; Pickkers P
    Ned Tijdschr Geneeskd; 2014; 158():A6859. PubMed ID: 24518844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls.
    Ankawi G; Neri M; Zhang J; Breglia A; Ricci Z; Ronco C
    Crit Care; 2018 Oct; 22(1):262. PubMed ID: 30360755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new normal: immunomodulatory agents against sepsis immune suppression.
    Hutchins NA; Unsinger J; Hotchkiss RS; Ayala A
    Trends Mol Med; 2014 Apr; 20(4):224-33. PubMed ID: 24485901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances.
    Skirecki T; Borkowska-Zielińska U; Złotorowicz M; Hoser G
    Arch Immunol Ther Exp (Warsz); 2012 Apr; 60(2):123-35. PubMed ID: 22301668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cellular events in the pathophysiology of sepsis.
    Bhan C; Dipankar P; Chakraborty P; Sarangi PP
    Inflamm Res; 2016 Nov; 65(11):853-868. PubMed ID: 27392441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Sepsis-Induced Immunosuppression.
    Venet F; Rimmelé T; Monneret G
    Crit Care Clin; 2018 Jan; 34(1):97-106. PubMed ID: 29149944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protracted immune disorders at one year after ICU discharge in patients with septic shock.
    Riché F; Chousterman BG; Valleur P; Mebazaa A; Launay JM; Gayat E
    Crit Care; 2018 Feb; 22(1):42. PubMed ID: 29467023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balance between Hyperinflammation and Immunosuppression in Sepsis.
    Yadav H; Cartin-Ceba R
    Semin Respir Crit Care Med; 2016 Feb; 37(1):42-50. PubMed ID: 26820273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory therapies in sepsis.
    Kox WJ; Volk T; Kox SN; Volk HD
    Intensive Care Med; 2000; 26 Suppl 1():S124-8. PubMed ID: 10786969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of high cut off membranes in renal replacement therapy of acute kidney injury in the course of sepsis - the current state of knowledge].
    Kade G; Spaleniak S
    Pol Merkur Lekarski; 2018 Sep; 45(267):99-101. PubMed ID: 30240377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.